Skip to main content

Assoc. Prof. Cengiz Dibekoğlu, MD

General Surgeon · Laparoscopic · Robotic · Oncologic Surgery

Research area · Emerging treatment technologies

PROTACs — targeted protein degradation

Araştırma alanı dosyası (tek çalışma değil): hedefli protein yıkımı / PROTAC

Record type
Treatment-technology research area (not a single NCT)
Evidence level
2026 phase I clinical activity signal for KRAS G12D degrader setidegrasib (ASP3082) in NEJM; not standard care.
Linked records
1

Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.

Scope
Pancreas, Multiple / solid tumors — Araştırma alanı — alt kartlarda tümör tipine göre
How it works
Classic inhibitors try to temporarily silence a protein. PROTACs recruit the ubiquitin–proteasome system to degrade the target and reduce its abundance.
Translational distance
First-in-human clinical signals exist; not approved standard care. Mechanistically distinct from classic KRAS inhibitors (e.g., MRTX1133).
Example targets
Örn. KRAS G12D (setidegrasib)

For patients

What is being studied? Some new drugs try to reduce a harmful cancer protein by sending it to the cell’s own disposal system, not only silencing it. Not standard care yet.

Why promising? Degradation may open a path for formerly ‘undruggable’ targets such as KRAS G12D; especially relevant for pancreas cancer research.

What is not proven? Standard care; long-term survival superiority; equal efficacy across all PROTACs.

Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.

For clinicians

Site priority: very high. Setidegrasib NEJM 2026; NCT05382559. Nature Medicine highlight on PROTAC clinical test. MRTX1133 is an inhibitor — not linked here.

Cancer / population: Pancreas, Multiple / solid tumors — Araştırma alanı — alt kartlarda tümör tipine göre

Intervention: Proteoliz hedefleyen kimerik moleküller (PROTAC / degrader)

Primary endpoint: Alan düzeyinde tek primer sonlanım yok

Limitations: Erken klinik; PDAC ORR/PFS erken kohort sinyali — regülatör onay yok.

Real studies in this area

Each card is a separate clinical or discovery record — not one NCT.

Sources

← Back to explorer

AppointmentWhatsAppMessageTumor boardRequest